Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacyclics Xcytrin NDA in late 2006

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pharmacyclics will submit an NDA for Xcytrin (motexafin gadolinium) for treatment of patients with brain metastases with non-small cell lung cancer, the firm announces May 9. The company claims that recent analyses of its failed Phase III SMART trial show that while overall results announced in December revealed no significant improvement in progression or survival, statistical significance was achieved in the study's North American subpopulation (1Pharmaceutical Approvals Monthly January 2006, In Brief). Pharmacyclics says it has discussed the findings with FDA. SMART (Study of Neurologic Progression with Motexafin Gadolinium & Radiation Therapy) will be presented at the American Society of Clinical Oncology meeting in Atlanta on June 3...

You may also be interested in...



Pharmacyclics Xcytrin misses endpoint

Pharmacyclics' Xcytrin (motexafin gadolinium) fails to show statistical significance for lung cancer patients with brain metastases in the 554-patient Phase III SMART (Study of Neurologic Progression with Motexafin Gadolinium And Radiation Therapy) trial, the firm reports Dec. 19. For the primary endpoint of time to neurologic progression (TNP), patients receiving whole brain radiation therapy plus Xcytrin had a median TNP of 15.4 months compared to 10 months for patients receiving radiation alone (p=0.122, hazard ratio=0.78). Pharmacyclics also notes there was "no significant difference in survival," a secondary endpoint. The firm plans to discuss the results with FDA; three trials looking at Xcytrin as a systemic therapy for relapsed lung cancer are ongoing...

IPO Year In Review: Record-Year Bodes Well For 2021, And For More SPACs

Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.

Abbott Capitalizes On Pandemic Testing Boom; Device Sales Stay Almost Flat

Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.

Topics

UsernamePublicRestriction

Register

OM013202

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel